Peptipedia
CognitiveIn Clinical TrialsClinical Trials

ARA-290

Also known as Cibinetide, ARA 290

An 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor. No erythropoietic effects.

Phase II/III Clinical Trials - Orphan Drug Designation (US/EU)
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

4 mg daily

Frequency

Once daily

Duration

28-day courses in trials

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 4 mg daily via Subcutaneous injection, Once daily. Dose range: 4-8 mg daily. Duration: 28-day courses in trials.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Once daily.

Mechanism of Action

Selectively activates the innate repair receptor (IRR), triggering anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production.

Research Summary

Evidence level: clinical trials. Clinical status: Phase II/III Clinical Trials - Orphan Drug Designation (US/EU).

Side Effects & Safety

Important Warnings

  • No erythropoietic effects (no blood thickening)
Injection site reactions
generally well-tolerated in trials

References

No references available.

Related Peptides

Browse all →
SelankCognitive

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

View profile
SemaxCognitive

Synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Used clinically in Russia for stroke, traumatic brain injury, and cognitive disorders.

View profile
CerebrolysinCognitive

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

View profile